23651-62-9

Basic information

• Product Name: ethyl N-ethyl-beta-alaninate
• Synonyms: ethyl N-ethyl-beta-alaninate;N-Ethyl-β-alanine ethyl ester;Einecs 245-806-5;.beta.-Alanine, N-ethyl-, ethyl ester;3-ethylaminopropanoic acid ethyl ester;ethyl 3-ethylaminopropanoate
• CAS NO: 23651-62-9
• Molecular Formula: C₇H₁₅NO₂
• Molecular Weight: 145.1995
• EINECS: 245-806-5
• Mol File: 23651-62-9.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 195.2°Cat760mmHg
• Flash Point: 71.8°C
• Appearance: /
• Density: 0.928g/cm³
• PKA: 9.55±0.19(Predicted)
• CAS DataBase Reference: ethyl N-ethyl-beta-alaninate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl N-ethyl-beta-alaninate(23651-62-9)
• EPA Substance Registry System: ethyl N-ethyl-beta-alaninate(23651-62-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 23651-62-9(Hazardous Substances Data)

Usage

General Description

Ethyl N-ethyl-beta-alaninate is a chemical compound with the molecular formula C8H17NO2. It is a derivative of beta-alanine, an amino acid that is a component of carnosine, and is commonly used in the synthesis of pharmaceuticals and agrochemicals. Ethyl N-ethyl-beta-alaninate is known for its ability to act as a chiral catalyst in various chemical reactions, and it is also used as a flavoring agent in food products. It is a colorless liquid with a fruity odor and is considered to be relatively stable under normal conditions. Additionally, it is important to handle ethyl N-ethyl-beta-alaninate with caution as it may cause irritation to the skin, eyes, and respiratory system upon exposure.

Upstream product

• 75-04-7 ethylamine 
• 140-88-5 ethyl acrylate 
• 109-89-7 diethylamine 
• 1094629-96-5 ethyl 3-(benzyl(ethyl)amino)propanoate 
• 539-74-2 Ethyl 3-bromopropionate 

Downstream Products

• 4320-43-8 3-ethylamino-1,1-diphenyl-propan-1-ol 
• 114171-58-3 ethyl 2-amino-5-fluoro-6-(p-tolylthio)nicotinate 
• 114171-70-9 2-amino-5-fluoro-6-(p-tolylthio)nicotinonitrile 
• 113237-22-2 ethyl 6-(4-acetyl-1-piperazinyl)-2-ethylamino-5-fluoronicotinate 
• 82671-05-4 ethyl 6-(4-acetyl-1-piperazinyl)-2-amino-5-fluoronicotinate 
• 77498-12-5 (S)-2-[(2-Ethoxycarbonyl-ethyl)-ethyl-carbamoyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid benzyl ester 
• 74011-58-8 enoxacine 
• 114190-30-6 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(p-tolylthio)-1,8-naphthyridine-3-carboxylic acid 
• 114171-68-5 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(p-tolylsulfonyl)-1,8-naphthyridine-3-carboxylic acid 
• 114171-60-7 ethyl 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(p-tolylthio)-1,8-naphthyridine-3-carboxylate 
• 114171-72-1 ethyl 1-ethyl-6-fluoro-1,2-dihydro-4-hydroxy-7-(p-tolylthio)-1,8-naphthyridine-3-carboxylate 
• 114171-59-4 ethyl 4-amino-1-ethyl-6-fluoro-1,2-dihydro-7-(p-tolylthio)-1,8-naphthyridine-3-carboxylate 
• 23690-07-5 ethyl-(3,3-diphenyl-allyl)-amine 

Relevant articles and documents

Regioselective γ-alkylation of tert-butyl 2,4-dioxopiperidine-1- carboxylate

A method for the regioselective γ-alkylation of N-Boc protected piperidine-2,4-dione is reported. The use of a wide variety of electrophiles demonstrates the robustness of the procedure. The reaction offers facile access to synthetically useful derivatives. A mechanistic hypothesis is given, explaining the essential role played by the lithium counter-ion. Georg Thieme Verlag Stuttgart.

HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF

The present invention relates to the technical field of pharmaceuticals. Specifically, the present invention relates to a halo-allylamine compound, or a pharmaceutically acceptable salt, an ester, a stereoisomer or a tautomer thereof, and a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, and use in preventing and/or treating a disease related to or mediated by the SSAO/VAP-1 protein,wherein R1, R2, R3, R4, R5, R6, L1 and Cy1 are defined in the specification.

New disulfiram derivatives as magl-selective inhibitors

Monoacylglycerol lipase (MAGL) is a key enzyme in the human endocannabinoid system. It is also the main enzyme responsible for the conversion of 2-arachidonoyl glycerol (2-AG) to arachidonic acid (AA), a precursor of prostaglandin synthesis. The inhibition of MAGL activity would be beneficial for the treatment of a wide range of diseases, such as inflammation, neurodegeneration, metabolic disorders and cancer. Here, the author reports the pharmacological evaluation of new disulfiram derivatives as potent inhibitors of MAGL. These analogues displayed high inhibition selectivity over fatty acid amide hydrolase (FAAH), another endocannabinoid-hydrolyzing enzyme. In particular, compound 2i inhibited MAGL in the low micromolar range. However, it did not show any inhibitory activity against FAAH.